| |
 |
Hyundai Pharmaceutical is a leading partner for global companies aiming to enter the Korean pharmaceutical market efficiently and successfully. With extensive expertise in clinical trials, regulatory affairs, and marketing, Hyundai Pham provides unmatched support to ensure swift market penetration and long-term stability.
We specialize in advancing innovative healthcare solutions, working closely with global partners to conduct simultaneous multinational trials, enabling rapid product launches in Korea. Hyundai Pharm is committed to improving patient outcomes by offering high-quality, innovative drugs that address critical health needs.
Our strategic partnerships range from co-marketing and co-promotion to joint ventures and equity investments, allowing us to explore diverse collaboration opportunities that drive value creation.
Therapeutic Focus Areas:
- Women’s health
- Pain management (e.g., post-operative pain management)
- Cardiovascular diseases (e.g., hypertension)
- Endocrine disorders (e.g., Type I/II Diabetes and complications)
- CNS disorders (e.g., depression, schizophrenia, Alzheimer's, Parkinson's)
- Respiratory conditions
- Oncology
If you are interested in exploring partnership opportunities, please reach out to us at (BD@hdpharm.co.kr)
|
 |
|
YEAR |
EVENT |
2024 |
Sol-Gel (Israel)
Exclusive License Agreement for Twyneo, combination treatment for acne vulgaris, and Epsolay, treatment for rosacea
Theramex (UK)
Exclusive Distribution Agreement for Bijuva, a product for menopausal hormone therapy (MHT)
|
2023 |
CASSIOPEA (Italy)
Exclusive License Agreement for Winlevi, a first-in-class topical treatment for acne vulgaris
Janssen Korea
Exclusive Distribution and Promotion Agreement for Topamax, a medicine to treat epilepsy and migraine
|
2022 |
ASKA Pharmaceutical (Japan)
Exclusive License and Supply Agreement for Slinda, an estrogen-free progestin only oral contraceptive
|
2020 |
Linepharma International (UK)
Exclusive Marketing and Distribution Agreement for Mifegymiso,
a combination product for the medical termination of a
pregnancy
Ferring Pharmaceuticals Korea
Co-Promotion Agreement for three women’s health products (Tractocile Injection, Duratocin RTS Injection, Propess Vaginal SR Tablet)
Sandoz Korea
Co-Promotion Agreement for three anti-depressant products (Escitalopram Tablet, Sertraline Tablet, Paroxetine Tablet)
|
2019 |
NEUROCHLORE (France)
Exclusive License Agreement for the Autism Spectrum Disorder treatment candidate
Seoul Saint Mary’s Hospital & KRICT (Korea)
Exclusive License Agreement for the “Composition for Hardening Soft Tissue”
BAUSCH & LOMB (USA)
Exclusive Distribution Agreement for Emerade, an adrenaline auto-injector for anaphylaxis
|
2018 |
MITHRA Pharmaceuticals (Belgium)
Exclusive License and Supply Agreement for Estelle, a novel combined oral contraceptive (COC) product candidate
|
2016 |
ACERUS Pharmaceuticals (Canada)
Exclusive License and Supply Agreement for Natesto, a testosterone nasal gel for replacement therapy in adult males
|
2015 |
ASLAN Pharmaceuticals (Singapore)
Collaboration and License Agreement for ASLAN001 (Varlitinib), a drug candidate for the treatment of advanced biliary tract cancer
Takeda Korea
Exclusive Distribution Agreement for Tachosil (Pre-rolled), a dual action surgical hemostatic patch
CHEMO (Spain)
Exclusive License and Supply Agreement for Lania (Levonorgestrel, Ethinyl Estradiol), a generic combined oral contraceptive (COC) product
Pfizer Korea
Co-Promotion Agreement for Duavive, a product for menopausal
hormone therapy (MHT)
Abbott Korea
Co-Promotion Agreement for Hokunalin Patch, a treatment of relief of various symptoms, such as dyspnea, resulting from airway obstruction in bronchial asthma, acute bronchitis, chronic bronchitis, and pulmonary emphysema
|
2014 |
DUCHESNAY (Canada)
Exclusive License and Supply Agreement for Dicletin, a product for
treating nausea and vomiting in pregnancy
CHEMO (Spain)
Exclusive License and Supply Agreement for Bonita (Desogestrel, Ethinyl Estradiol), a generic combined oral contraceptive (COC) product
|
2012 |
Takeda Korea
Exclusive Distribution Agreement for Tachosil, a dual action surgical hemostatic patch
|
2011 |
Bausch & Lomb South Asia Inc. (Korea)
Co-Promotion Agreement for Ocuvite, an eye vitamin and mineral
supplements with Lutein
Ophtecs (Japan)
Exclusive License and Supply Agreement for Ruping, a preservativefree artificial tear
|
|
|
